Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: Impact of long repeats of CNR1

Pharmacogenomics Journal

Volumn 10, Issue 3, 2010, Pages 232-242

  Proudnikov, D ^a   Kroslak, T ^a   Sipe, J C ^b   Randesi, M ^a   Li, D ^a,c   Hamon, S ^a   Ho, A ^a   Ott, J ^a,d   Kreek, M J ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Chinese Academy of Sciences and China National Center for Bioinformation   (China)

Author keywords

CB1; CNR1; Drug addiction; FAAH; Haplotypes; SNPs

Indexed keywords

CANNABINOID 1 RECEPTOR; FATTY ACID AMIDASE;

AFRICAN AMERICAN; ALLELE; ARTICLE; ASIAN; CAUCASIAN; CONTROLLED STUDY; ETHNIC DIFFERENCE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE; HEROIN DEPENDENCE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN AMERICANS; AMIDOHYDROLASES; BEHAVIOR, ADDICTIVE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; HEROIN DEPENDENCE; HUMANS; MALE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, CANNABINOID, CB1; TRINUCLEOTIDE REPEATS;

EID: 77952885520     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2009.59     Document Type: Article

References (48)

1. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990; 87: 1932-1936.
2. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991; 11: 563-583.
3. Tsou K, Brown S, Sañudo-Peña MC, Mackie K, Walker JM. Immunohis-tochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998; 83: 393-411.
4. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of peripheral receptor for cannabinoids. Nature 1993; 365: 61-65.
5. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005; 310: 329-332.
6. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. International Union of Pharmacology. XXVII. Classification of cannabi-noid receptors. Pharmacol Rev 2002; 54: 161-202.
7. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-1949.
8. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215: 89-97.
9. Deutsch DG, Ueda N, Yamamoto S. The fatty acid amide hydrolase (FAAH). Prostaglandins Leukot Essent Fatty Acids 2002; 66: 201-210.
10. McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Ann Rev Biochem 2005; 74: 411-432.
11. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001; 98: 9371-9376.
12. Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA 2002; 99: 8394-8399.
13. Chiang KP, Gerber AL, Sipe JC, Cravatt BF. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet 2004; 13: 2113-2119.
14. Navarro M, Chowen J, Carrera MRA, del Arco I, Villanúa MA, Martin Y et al. CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. Neuroreport 1998; 9: 3397-3402.
15. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 2001; 21: 5344-5350.
16. De Vries TJ, Homberg JR, Binnekade R, Raasø H, Schoffelmeer AN. Cannabinoid modulation of the reinforcing and motivational properties of heroin-associated cues in rats. Psychopharmacology 2003; 168: 164-169.
17. Mascia MS, Obinu MC, Ledent C, Parmentier M, Böhme GA, Imperato A et al. Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB (1) receptor knockout mice. Eur J Pharmacol 1999; 383: R1-R2.
18. Cossu G, Ledent C, Fattore L, Imperato A, Böhme GA, Parmentier M et al. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 2001; 118: 61-65.
19. Caenazzo L, Hoehe MR, Hsieh WT, Berrettini WH, Bonner TI, Gershon ES. HindIII identifies a two allele DNA polymorphism of the human cannabinoid receptor gene (CNR). Nucleic Acids Res 1991; 19: 4798.
20. Gadzicki D, Müller-Vahl K, Stuhrmann M. A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol Cell Probes 1999; 13: 321-323.
21. Zhang PW, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walther D et al Human cannabinoid receptor 1:5 exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry 2004; 9: 916-931.
22. Hoehe MR, Caenazzo L, Martinez MM, Hsieh WT, Modi WS, Gershon ES et al. Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14-q15. New Biol 1991; 3: 880-885.
23. Tsai SJ, Wang YC, Hong CJ. Association study between cannabinoid receptor gene (CNR1) and pathogenesis and psychotic symptoms of mood disorders. Am J Med Genet 2001; 105: 219-221.
24. Tsai SJ, Wang YC, Hong CJ. Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia. Psychiatr Genet 2000; 10: 149-151.
25. Ujike H, Takaki M, Nakata K, Tanaka Y, Takeda T, Kodama M et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 2002; 7: 515-518.
26. Seifert J, Ossege S, Emrich HM, Schneider U, Stuhrmann M. No association of CNR1 gene variations with susceptibility to schizophrenia. Neurosci Lett 2007; 426: 29-33.
27. Comings DE, Muhleman D, Gade R, Johnson P, Verde R, Saucier G et al. Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol Psychiatry 1997; 2: 161-168.
28. Li T, Liu X, Zhu ZH, Zhao J, Hu X, Ball DM et al. No association between (AAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population. Mol Psychiatry 2000; 5: 128-130.
29. Rettig RA, Yarmolinsky A (eds) Federal Regulation of Methadone Treatment. National Academy of Sciences. National Academy Press: Washington, DC, 1995.
30. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC 1994.
31. Kellogg SH, McHugh PF, Bell K, Schluger JH, Schluger RP, LaForge KS et al. The Kreek-McHugh-Schluger-Kellogg scale: a new, rapid method for quantifying substance abuse and its possible applications. Drug Alcohol Depend 2003; 69: 137-150.
32. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 1998; 95: 9608-9613.
33. Everitt BS. The Analysis of Contingency Tables, 2nd edn. Chapman & Hall/CRC: Boca Raton, FL, 1992.
34. Agresti A. Categorical Data Analysis, 2nd edn. Wiley-Interscience: Hoboken, NJ, 2002.
35. Hoh J, Wille A, Ott J. Trimming, weighting, and grouping SNPs in human case-control association studies. Genome Res 2001; 11: 2115-2119.
36. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
37. Ballon N, Leroy S, Roy C, Bourdel MC, Charles-Nicolas A, Krebs MO et al. (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. Pharmacogenomics J 2006; 6: 126-130.
38. Heller D, Schneider U, Seifert J, Cimander KF, Stuhrmann M. The cannabinoid receptor gene (CNR1) is not affected in German i.v. drug users. Addict Biol 2001; 6: 183-187.
39. Schmidt LG, Samochowiec J, Finckh U, Fiszer-Piosik E, Horodnicki J, Wendel B et al. Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depend 2002; 65: 221-224.
40. Preuss UW, Koller G, Zill P, Bondy B, Soyka M. Alcoholism-related phenotypes and genetic variants of the CB1 receptor. Eur Arch Psychiatr Clin Neourosci 2003; 253: 275-280.
41. Leroy S, Griffon N, Bourdel MC, Olié JP, Poirier MF, Krebs MO. Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. Am J Med Genet 2001; 105: 749-752.
42. Zammit S, Spurlock G, Williams H, Norton N, Williams N, O'Donovan MC et al. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatry 2007; 191: 402-407.
43. Hamdani N, Tabeze JP, Ramoz N, Ades J, Hamon M, Sarfati Y et al. The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia. Eur Neuropsychopharmacol 2008; 18: 34-40.
44. Herman AI, Kranzler HR, Cubells JF, Gelernter J, Covault J. Association study of the CNR1 gene exon 3 alternative promoter region polymorphisms and substance dependence. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 499-503.
45. Zuo L, Kranzler HR, Luo X, Covault J, Gelernter J. CNR1 variation modulates risk for drug and alcohol dependence. Biol Psychiatry 2007; 62: 616-626.
46. Morita Y, Ujike H, Tanaka Y, Uchida N, Nomura A, Ohtani K et al. A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia. Neurosci Lett 2005; 376: 182-187.
47. Flanagan JM, Gerber AL, Cadet JL, Beutler E, Sipe JC. The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum Genet 2006; 120: 581-588.
48. Tyndale RF, Payne JI, Gerber AL, Sipe JC. The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in Caucasians. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 660-666.